Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab in Japanese patients with acquired thrombotic thrombocytopenic purpura
NCT04074187Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 3 trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Sanofi. Started Oct 2019; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT04074187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074187.